C18orf54 Inhibitors
Chromosome 18 Open Reading Frame 54 (C18orf54) is a protein encoded by a gene located on chromosome 18 within a specified open reading frame (ORF). This nomenclature provides a systematic way to reference the gene before its function is elucidated. The study of C18orf54 would typically involve various experimental approaches to uncover its role in cellular physiology, including its expression pattern, post-translational modifications, and interaction with other cellular components.
Since the function of C18orf54 is not explicitly known, it could be involved in a myriad of cellular processes, such as gene regulation, signal transduction, intracellular transport, or metabolism. The protein could also be specific to certain cell types, developmental stages, or environmental responses, contributing to the complexity and specificity of cellular function.Understanding the role of C18orf54 may involve investigating its protein structure, domains that suggest potential functions or interactions, and conservation across species. Comparative genomics could indicate a conserved biological role if the protein is found in a wide range of organisms. Functional studies, such as gene knockdown or overexpression experiments, could help reveal its role in cellular or organismal physiology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and proliferation. If C18orf54 is involved in related pathways, mTOR inhibition could indirectly affect processes involving C18orf54. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits protein synthesis in eukaryotic organisms. If C18orf54 is involved in protein synthesis regulation, its function might be indirectly influenced by this inhibitor. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor, altering chromatin structure and gene expression. This could indirectly affect C18orf54 expression if it's regulated epigenetically. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. If C18orf54 is involved in PI3K/Akt signaling pathways, it could indirectly impact its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If C18orf54 is involved in signaling regulated by p38 MAPK, this inhibitor might indirectly influence its function. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib inhibits proteasome activity. If C18orf54 is involved in protein degradation pathways or is regulated by ubiquitination, this inhibitor could indirectly affect its function. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide modulates the expression of various cytokines and growth factors. If C18orf54 is part of cytokine-regulated pathways, it might have an indirect influence. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor. Similar to Bortezomib, it could indirectly affect C18orf54 function if the protein is involved in protein degradation or ubiquitin-dependent processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of PI3K. It might indirectly affect C18orf54, particularly if it is involved in PI3K-regulated pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which could indirectly affect C18orf54 activity if the protein is involved in the MAPK/ERK pathway. | ||||||